Vivani Medical is trading at $1.34, up 9.84% in pre-market, with no fresh company-specific announcement identified to explain the October 6 move. - The latest prominent company news was the August 6 completion of dosing for all participants in the SLIM-1 Phase 1 trial; this is prior context, not a confirmed catalyst. - The broader market backdrop is modestly positive, but supplied major-index moves are below 0.5% and do not establish a market-wide explanation. No volume or activity data was provided.